Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This article was retracted on 06 February 2021

This article has been updated

Abstract

Alendronate decreases the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX; about 45% at 3 months) and serum levels of alkaline phosphatase (ALP; about 27% at 24 months), leading to an increase in lumbar spine bone mineral density (BMD; about 9% at 24 months) in postmenopausal Japanese women with osteoporosis. However, the effectiveness of oral bisphosphonates on osteoporosis remains to be established in patients who have undergone a gastrectomy. The objective of the present case series study was to examine the effect of alendronate on BMD and bone turnover markers in post-gastrectomy osteoporotic patients. Sixteen patients (3 men and 13 postmenopausal women) with osteoporosis, who had undergone a gastrectomy (mean age: 69.1 years), were recruited in our outpatient clinic. All the patients were treated with alendronate (5 mg daily or 35 mg weekly) for 24 months. The effects of alendronate on lumbar spine (women) or total hip (men) BMD and urinary NTX and serum ALP levels were examined. A total or partial gastrectomy had been performed for eight patients each. The mean duration after surgery was 16.0 years. With alendronate therapy, urinary NTX levels significantly decreased at 3 months (−27.0%). Serum ALP levels decreased (−12.1%) and lumbar spine BMD increased (+5.2%), but total hip BMD did not significantly change (+0.6%) at 24 months. No severe adverse events were observed, and alendronate therapy was well tolerated. These results suggest that alendronate mildly increases lumbar spine BMD by mildly reducing bone turnover in osteoporotic patients after a gastrectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanism of action of bisphosphonate. Bone 24:73S–79S

    Article  CAS  Google Scholar 

  2. Iwamoto J, Takeda T, Sato Y (2006) Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 22:919–928

    Article  CAS  Google Scholar 

  3. Iwamoto J, Takeda T, Sato Y (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis—usefulness of alendronate and risedronate. Expert Opin Pharmacother 8:2743–2756

    Article  CAS  Google Scholar 

  4. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483–489

    Article  Google Scholar 

  5. Lin JH, Chen IW, deLuna FA (1994) On the absorption of alendronate in rats. J Pharm Sci 83:1741–1746

    Article  CAS  Google Scholar 

  6. Fliech H (2001) Bisphosphonates in bone disease from the laboratory to the patient, 4th edn. Academic Press, London, pp 64–71

    Google Scholar 

  7. Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:15–28

    Article  Google Scholar 

  8. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288–298

    Article  CAS  Google Scholar 

  9. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150

    Article  Google Scholar 

  10. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  CAS  Google Scholar 

  11. Fukunaga M, Sone T (2003) Guideline for diagnosis and therapy of osteoporosis from a point of view of sex difference. Clin Calcium 13:1399–1404 (in Japanese)

    PubMed  Google Scholar 

  12. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10:183–192

    Article  CAS  Google Scholar 

  13. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H (2002) The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 63:606–620

    Article  CAS  Google Scholar 

  14. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388

    Article  CAS  Google Scholar 

  15. Tsuboi M, Nagamatsu S (1998) A comparison of dynamics of alendronate between elderly and non-elderly women. Shinryo-to-Shinyaku 1:43–49 (in Japanese)

    Google Scholar 

  16. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221

    Article  CAS  Google Scholar 

  17. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97–104

    Article  Google Scholar 

  18. Liedman B (1999) Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients—is reconstruction with a reservoir worthwhile? Nutrition 15:677–682

    Article  CAS  Google Scholar 

  19. Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI (2007) High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol 13:6492–6497

    Article  CAS  Google Scholar 

  20. Iba K, Wada T, Takada J, Yamashita T (2003) Multiple insufficiency fractures with severe osteoporosis. J Orthop Sci 8:717–720

    Article  Google Scholar 

  21. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501

    Article  CAS  Google Scholar 

  22. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–329

    Article  CAS  Google Scholar 

  23. Duques P, Araujo RSA, de Amorim WPD (2001) Esophagus-enteric anastomosis ulceration caused by alendronate. Arq Gastroenterol 38:129–131

    Article  CAS  Google Scholar 

  24. Tovey FI, Hall ML, Ell PJ, Hobsley M (1992) A review of postgastrectomy bone disease. J Gastroenterol Hepatol 7:639–645

    Article  CAS  Google Scholar 

  25. Bisballe S, Buus S, Lund B, Hessov I (1986) Food intake and nutritional status after gastrectomy. Hum Nutr Clin Nutr 40:301–308

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We have no funding sources.

Conflict of interest statement

We have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Jun Iwamoto, Tsuyoshi Takeda & Hideo Matsumoto

  2. Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan

    Mitsuyoshi Uzawa

  3. Department of Neurology, Mitate Hospital, Fukuoka, Japan

    Yoshihiro Sato

Authors
  1. Jun Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuyoshi Uzawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsuyoshi Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideo Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Iwamoto.

About this article

Cite this article

Iwamoto, J., Uzawa, M., Sato, Y. et al. RETRACTED ARTICLE: Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. J Bone Miner Metab 28, 202–208 (2010). https://doi.org/10.1007/s00774-009-0116-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-009-0116-0

Keywords

Search

Navigation